• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Streamex Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    2/9/26 4:30:46 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STEX alert in real time by email
    false 0001530766 0001530766 2026-02-03 2026-02-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    February 3, 2026

    Date of Report (Date of earliest event reported)

     

    STREAMEX CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38659   26-4333375
    (State   (Commission   (I.R.S. Employer
    of incorporation)   File Number)   Identification Number)

     

    2431 Aloma Avenue, Suite 243

    Winter Park, Florida 32792

    (Address of principal executive offices) (Zip code)

     

    (203) 409-5444

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   STEX   The NASDAQ Stock Market LLC

      

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On February 3, 2026, the board of directors (the “Board”) of Streamex Corp. (the “Company”) appointed Mr. Anthony Marciano as an independent director on the Board for a term expiring at the next annual meeting of the Company’s stockholders or until his successor is duly elected and qualified, or his earlier death, resignation or removal, and as a member of the Audit Committee.

     

    Anthony Marciano, age 64, joins the Board bringing more than 40 years of experience in finance and academics. Anthony Marciano is a Clinical Professor of Finance at the Leonard N. Stern School of Business at New York University, a position he has held since August 2007. Professor Marciano teaches corporate finance courses to MBA students, undergraduates, and executives, and has overseen the Michael Price Student Investment Fund. He has been named to BusinessWeek's list of outstanding faculty. Prior to joining NYU Stern, he taught advanced corporate finance and M&A courses at MIT Sloan School of Management and served as a Clinical Professor of Finance at the University of Chicago Graduate School of Business from 1994-2006. Earlier in his career, Marciano held senior positions at Goldman Sachs, Morgan Stanley, and Drexel Burnham Lambert. He earned his MBA from MIT Sloan School of Management and his BA in Computer Science from Dartmouth College. Mr. Marciano’s deep expertise in management and finance positions him as a highly valuable asset to our Board.

     

    On February 3, 2026, Mr. Marciano executed an offer letter (the “Marciano Offer Letter”) with the Company in connection with his appointment. As set forth in the Marciano Offer Letter, Mr. Marciano will receive compensation consistent with the Company’s non-employee director compensation policy as in effect from time to time. Under the Company’s current policy, Mr. Marciano is entitled to an annual cash retainer of $40,000, as well as an additional annual retainer of $25,000 for each Board committee on which he serves. Mr. Marciano is also eligible to receive annual equity compensation, the amount and form of which will be determined by the Compensation Committee in accordance with the Company’s equity compensation policies.

     

    The foregoing summary is qualified in its entirety by reference to the Marciano Offer Letter, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1 and which is incorporated herein by reference.

     

    There are no arrangements or understandings between Mr. Marciano and any other person pursuant to which Mr. Marciano was selected as a director. There are no transactions in which Mr. Marciano has an interest requiring disclosure under item 404(a) of Regulation S-K.

     

    Item 8.01 Other Events.

     

    On February 4, 2026, the Company issued a press release announcing the appointment of Anthony Marciano to its Board.

     

    A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Number   Description
    10.1   Offer Letter, dated February 3, 2026
    99.1   Press Release, dated February 4, 2026
    104   Cover Page Interactive Data File (formatted as Inline XBRL)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: February 9, 2026 By: /s/ Karl Henry McPhie
      Name: Karl Henry McPhie
        Title: Chief Executive Officer

     

     

    Get the next $STEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STEX

    DatePrice TargetRatingAnalyst
    11/25/2025$12.00Buy
    Needham
    More analyst ratings

    $STEX
    SEC Filings

    View All

    Streamex Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    2/9/26 4:30:46 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events

    8-K - Streamex Corp. (0001530766) (Filer)

    1/27/26 4:54:27 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Streamex Corp. (0001530766) (Filer)

    1/27/26 4:51:15 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Giustra Frank bought $317,000 worth of shares (100,000 units at $3.17) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/4/26 7:04:10 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lekstrom Morgan Lee bought $71,910 worth of shares (23,500 units at $3.06) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/3/26 11:32:53 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lekstrom Morgan Lee bought $9,250 worth of shares (2,500 units at $3.70) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    1/29/26 3:30:48 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Streamex Corp. (NASDAQ: STEX) Co-Founder & Executive Chairman Provides Corporate Update

    WINTER PARK, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), an institutional-grade digital asset and real-world asset tokenization company, today provided a corporate update from its Co-Founder & Executive Chairman, Morgan Lekstrom, highlighting recent strategic progress, balance sheet strength, insider alignment, preparations for the upcoming launch of GLDY, and the 2026 strategic roadmap. Executive Chairman Commentary Morgan Lekstrom, Co-Founder & Executive Chairman of Streamex, commented: "Streamex now has a strong, well-capitalized foundation as we move toward the launch of GLDY. The Company is supported by an experienced leadersh

    2/10/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Appoints Morgan Lekstrom as Executive Chairman, and Announces Completed Repayment of Convertible Debenture and Cancellation of SEPA

    WINTER PARK, Fla., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced that its Co-Founder and Chairman, Morgan Lekstrom, has been named Executive Chairman and will join the executive leadership team. The Company has also announced that the previously entered into Secured Convertible Debentures with YA II PN, LTD., a Cayman Islands exempt limited company ("Yorkville" or "Holder") have been fully repaid and the Standby Equity Purchase Agreement (the "SEPA") previously entered into with Yorkville has been cancelled. "I am honoured and excited to step int

    2/9/26 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Appoints Anthony Marciano, Clinical Professor of Finance at NYU Stern to Board of Directors

    WINTER PARK, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced the appointment of Anthony Marciano, Clinical Professor of Finance at NYU Stern School of Business, to its Board of Directors. In this role, Marciano will bring deep expertise in corporate finance, mergers and acquisitions, and financial markets to strengthen Streamex's governance and strategic capital markets initiatives. He is joining as an independent director. "Anthony is an outstanding addition to our Board. His deep-rooted expertise in institutional finance, combined with a stro

    2/4/26 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Streamex Exchange Corporation with a new price target

    Needham initiated coverage of Streamex Exchange Corporation with a rating of Buy and set a new price target of $12.00

    11/25/25 7:59:34 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Giustra Frank bought $317,000 worth of shares (100,000 units at $3.17) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/4/26 7:04:10 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lekstrom Morgan Lee bought $71,910 worth of shares (23,500 units at $3.06) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/3/26 11:32:53 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lekstrom Morgan Lee bought $9,250 worth of shares (2,500 units at $3.70) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    1/29/26 3:30:48 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Leadership Updates

    Live Leadership Updates

    View All

    Streamex Corp. (NASDAQ: STEX) Appoints Morgan Lekstrom as Executive Chairman, and Announces Completed Repayment of Convertible Debenture and Cancellation of SEPA

    WINTER PARK, Fla., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced that its Co-Founder and Chairman, Morgan Lekstrom, has been named Executive Chairman and will join the executive leadership team. The Company has also announced that the previously entered into Secured Convertible Debentures with YA II PN, LTD., a Cayman Islands exempt limited company ("Yorkville" or "Holder") have been fully repaid and the Standby Equity Purchase Agreement (the "SEPA") previously entered into with Yorkville has been cancelled. "I am honoured and excited to step int

    2/9/26 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Appoints Anthony Marciano, Clinical Professor of Finance at NYU Stern to Board of Directors

    WINTER PARK, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced the appointment of Anthony Marciano, Clinical Professor of Finance at NYU Stern School of Business, to its Board of Directors. In this role, Marciano will bring deep expertise in corporate finance, mergers and acquisitions, and financial markets to strengthen Streamex's governance and strategic capital markets initiatives. He is joining as an independent director. "Anthony is an outstanding addition to our Board. His deep-rooted expertise in institutional finance, combined with a stro

    2/4/26 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Joins Solana Policy Institute in the Project Open Coalition to Advance Regulated On-Chain Trading of Real-World Assets, Including GLDY

    LOS ANGELES, Dec. 10, 2025 (GLOBE NEWSWIRE) --  Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization of real-world assets, today announced it has joined Project Open, a landmark initiative working to establish a regulated framework for the issuance and trading of securities on public blockchains. The effort aims to unlock billions in traditional asset value through 24/7 trading, instant settlement, lower costs, and enhanced transparency for all real-world assets, while keeping the United States competitive in financial innovation. Streamex joins Solana Policy Institute united to drive the next era of compliant digital market infrastructur

    12/10/25 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Financials

    Live finance-specific insights

    View All

    Streamex Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Investment Firm

    LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and real-world asset infrastructure, today announced that it has acquired a 9.9% equity interest in Empress Royalty Corp. ("Empress") (TSXV:EMPR) through a strategic share purchase from Terra Capital Natural Resources Fund Pty Ltd. ("Terra Capital"), a prominent institutional investor. Under the executed Share Purchase Agreement, Streamex acquired 12,671,297 common shares of Empress in exchange for 2,443,750 restricted common shares of Streamex at a US$5.00 STEX share price, representing a premium to the current market price of STEX and an

    12/11/25 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Announces Launch of $100,000,000 USD GLDY Pre-Sale – A Gold-Backed Yield Generating Stablecoin Offering Institutional Yield on Physical Gold Bullion

    The launch of Streamex's $100 million USD GLDY pre-sale marks a historic opportunity for gold investors. Investing in gold is no longer just a static store of value, Streamex, through GLDY has created a yield-generating, institutional grade asset designed to offer both spot gold exposure and yield paid in additional ounces of physical gold bullion.  Key Highlights Gold Price Exposure and Gold-Denominated Distributions: GLDY is designed to combine audited physical bullion holdings with yield from institutionally managed gold leases sourced through Monetary Metals. GLDY seeks to provide exposure to the price of gold while targeting periodic distributions paid in additional ounces of gold.Rev

    11/10/25 8:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care